In our study, at peak immunogenicity, there were no significant differences in the percentage of total CD4+ and CCR5+ CD4+ T cells with any of the vaccines, thus supporting our hypothesis that QS-21-containing vaccines do not increase target cells for HIV-1 infection. The gene discussed is CCR5; the disease is HIV-1 infection.